ITherapeutics ERUM Non-Confidential Information Presentation November 2022 Oral and IV treatment for serious bacterial infections ERUM 1 ITherapeutics Forward-looking Statements & Disclaimer This Confidential Overview (this "Overview") contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the granting or issuing of patents, the timing, progress and results of clinical trials, the ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief Executive Officer Judy Matthews – Chief Financial Officer Conference Call Participants Ed Acre – H.C. Wainwright Operator Ladies and gentlemen, welcome to the Iterum Therapeutics Third Quarter 2022 Financial Results Call. My name is Maxine, and I'll be coordinating the call today. [Operator Instructions] I will now ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2021 Earnings Conference Call March 28, 2022 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Thomas Yip - H.C. Wainwright Operator Hello, and welcome to the Iterum Therapeutics Fourth Quarter and Full Year 2021 Financial Results Call. My name is Alex, and I will be coordinating the call today. [Operator Instructions]. I ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2021 Earnings Conference Call November 12, 2021 8:30 AM ET Company Participants Corey Fishman – CEO Louise Barrett – Senior Vice President Legal Affairs Judy Matthews – CFO Conference Call Participants Gregory Renza – RBC Capital Markets Thomas Yip – H.C. Wainwright Operator Hello and welcome to the Iterum Therapeutic Q3 Financial Results Conference Call. My name is Alex and I will be your operator for today. [Operator Instructions] I'll now hand over to your host, L ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2021 Earnings Conference Call August 13, 2021 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Operator Hello and welcome to Iterum Therapeutics Q2 Financial Results Conference Call. Please note that all lines are currently on listen-only mode. [Operator Instructions] I now have the ple ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2021 Earnings Conference Call May 14, 2021 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Ed Arce - H.C. Wainwright Kevin Kedra - G Research Operator Ladies and gentlemen, welcome to the Iterum Therapeutics First Quarter 2021 Financial Results Conference Call. My name is Katie and I' ...

ITherapeutics ERUM Company Overview April 2021 Oral and IV treatment for serious bacterial infections ERUM 1 ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the expected timing of NDA and EMA filings and our plans, strategies and pro ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2020 Results Conference Call March 12, 2021 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - CEO Judy Matthews - CFO Conference Call Participants Gregory Renza - RBC Capital Markets Ed Arce - H.C. Wainwright Kevin Kedra - Gabelli Research Louise Barrett Good morning everyone and welcome to Iterum Therapeutics Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Conference Call. Our press release with the Company’ ...

ITherapeutics ERUM Company Overview February 2021 Oral and IV treatment for serious bacterial infections ERUM 1 ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the expected timing of NDA and EMA filings and our plans, strategies and ...

ITherapeutics ERUM Company Overview April, 2020 Oral and IV treatment for serious bacterial infections ERUM 1 ITherapeutics Forward-looking Statements & Disclaimer This presentation contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the sufficiency of cash resources, the granting or issuing of patents, the timing, progress and results of clinical trials, and the expected timin ...